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Background
Visceral leishmaniasis (VL) is a dis-
seminated protozoan infection caused by
the Leishmania donovani spp. complex
and is transmitted by phlebotomine sand
flies. Globally, over 200 million people
are at risk of contracting VL, and when
left untreated, the disease is universally
lethal. The human immunodeficiency
virus (HIV) pandemic has been one of
the main driving forces behind the
increased spread of VL over the last 20
years [1]. Sub-Saharan Africa is at the
epicentre of this detrimental synergy: in
East Africa, the most intense HIV-VL
interplay takes place, with HIV preva-
lence amongst VL cases ranging from
15% to more than 40% in certain areas
of Ethiopia and South Sudan. In this
region, the highly virulent L. donovani
prevails, and a large proportion of VL
patients present in advanced stages of
HIV infection.
Comorbidities of HIV and other infec-
tious diseases such as tuberculosis, crypto-
coccosis, or viral hepatitis manifest a
number of general characteristics includ-
ing accelerated disease progression, higher
rates of adverse outcomes, and therapy-
associated complications like the immune
reconstitution inflammatory syndrome
(IRIS) [2]. While HIV-VL coinfection is
also associated with accelerated HIV and
VL progression and a poor prognosis, it
appears to be governed by a number of
unique and poorly explained features.
One of these unique features is that even
after virological suppression under anti-
retroviral therapy (ART), patients often
remain clinically and immunologically in
a state of immunodeficiency and anergy,
with diffuse organ spread of parasites
[1,3]. Such patients are characterised by
high rates of anti-VL therapy failure,
which can be either primary failure or
recurring parasitological relapses. In other
patients, the unique entity of ‘‘active
chronic visceral leishmaniasis’’ was de-
scribed, entailing continuous asymptom-
atic parasite replication under therapy,
interspersed with symptomatic secondary
VL episodes [4]. The observed therapeu-
tic failure contrasts sharply with, e.g., the
IRIS events observed in other coinfec-
tions, which—while detrimental—are in-
dicative of a partial and possibly even
over-exuberant restoration of pathogen-
specific immune responses [2]. This
therapeutic failure in HIV-VL poses a
major challenge to programmes facing a
high burden of the coinfection—however,
it remains poorly understood and under-
researched.
VL Relapse in HIV-VL Patients:
Answered and Unanswered
Questions
A recent meta-analysis identified a
number of clinical risk factors for VL
relapse in HIV-VL patients, including
previous VL episodes, low baseline CD4+
T cell counts, an absence of CD4+ T cell
increase at follow-up, and an absence of
secondary prophylaxis [5]. At the mech-
anistic level, the precise processes under-
pinning VL relapse remain ill-charac-
terised: so far, this has only been
examined in animal models of coinfection
[6,7]. However, circumstantial evidence
suggests that, in the host-pathogen dyad,
parasite-related factors are less likely to
contribute to therapeutic failure, as mod-
ulation of drug susceptibility of parasites
in HIV-VL coinfection was either not
observed or could be adequately
explained by differences in past drug
exposure or transmission route [8,9].
Reinfection of HIV patients, rather than
true VL relapse, is likewise not strongly
supported by the existing evidence [10].
On the other hand, some evidence has
been garnered for the remaining expla-
nation—an aberrant immune response
[5,7].
Since successful anti-VL therapy is
known to require a protective Th1 im-
mune response, it is not unexpected to
observe VL relapses in severely immuno-
compromised HIV patients. However,
HIV patients on successful ART undergo
relatively rapid functional immune recon-
stitution and should—in similarity with the
IRIS-associated immune responses ob-
served in other coinfections—be able to
mount a response capable of clearing the
parasite during anti-VL treatment early
after therapy initiation, irrespective of the
stage of HIV infection. The failure of
coinfected patients to control VL under
ART and VL treatment thus alludes to a
persistent immunodeficiency or ‘‘damp-
ened’’ Th1 response as a consequence of
VL in these patients [11]. This may also
be reflected in the observed tolerance to
VL parasites in coinfected patients, where
immune responses to the parasite are
dampened despite high tissue parasite
loads. To better understand this persis-
tence, we must consider the mechanisms
by which VL manages to suppress the
immune system.
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A New Player in the Field
Immune suppression during VL ap-
pears to hinge on the production of IL-
10 (reviewed in [12]). Various immune
suppressive cell types have been implicated
in VL-associated immune suppression,
with varying degrees of evidence. The role
of regulatory T lymphocytes (Tregs) has
been assessed in multiple models (reviewed
in [13])—a contribution of Tregs to
persistent immune suppression under
ART cannot be ruled out, particularly as
several studies have documented a skewed
reconstitution of Tregs in the early phases
of ART, which could lead to a relative
dominance of the suppressive cell popula-
tion. However, it seems unlikely that Tregs
alone would be capable of mediating long-
term persistent immune suppression in
HIV-VL coinfection, as the Treg/T effec-
tor ratio tends to normalise following the
first few months of ART and, particularly,
as the functional contribution of Tregs to
VL is still questionable (reviewed in [12]).
Other cell types that have been implicated
in VL-associated immune suppression
include dendritic cells, mediating T lym-
phocyte suppression through IL-10-depen-
dent and -independent pathways [14], and
myeloid-derived suppressor cells (MDSC)
[15–18].
Here, we propose that MDSC may
contribute at least in part to the persistent
immune suppression underlying therapeu-
tic failure in HIV-VL patients. This little-
known cell type represents a heteroge-
neous population of immature myeloid
cells with marked antigen-specific immu-
nosuppressive capacities, elicited by (par-
tial) inhibition of myeloid cell maturation.
MDSC were first identified in models of
tumour immune evasion (reviewed in
[19]), but their functional contribution to
other models of immune evasion, such as
during parasitic infections, is increasingly
recognised [15,18]. Specifically, in the
context of leishmaniasis, a systemic expan-
sion of MDSC was observed in animal
models primed with leishmania parasites
[16,17]. As such, they could contribute at
least partially to VL-associated immune
suppression, in a similar fashion as ob-
served during tumour immune evasion,
potentially perturbing both T lymphocyte
proliferation and functionality [15]. Inter-
action with leishmania-specific T lympho-
cytes could even convert putative MDSC
to non-specific suppressor cells, further
exacerbating the HIV-VL-associated im-
mune dysfunction [20].
During VL in otherwise immunocom-
petent individuals, expansion of MDSC
populations could be an attempt at
keeping the detrimental excessive immune
response to VL and overall systemic
immune activation [21] in check. Further-
more, they may even contribute directly to
parasite control through production of
nitric oxide [22]. However, in severely
immunocompromised individuals such as
HIV-VL coinfected patients, the presence
of a dominant MDSC population—which,
as a myeloid cell population, would not
suffer HIV-mediated depletion on the
scale of the lymphocyte population—could
effectively prevent the immune system
from coming fully online under ART.
MDSC-mediated antigen-specific immune
suppression, while relatively innocuous
and possibly even beneficial in immuno-
competent individuals, could represent an
insurmountable obstacle for the reconsti-
tution of the VL-specific immune re-
sponse.
Testing the Hypothesis
The main barriers to testing this
hypothesis are of a logistical nature:
HIV-VL coinfections are prevalent in
sufficient numbers only in resource-poor
settings, where advanced functional im-
munological analysis is challenging and
establishing clinical cohorts is arduous.
However, if a dedicated research initiative
could overcome these challenges, the
hypothesis could be tested in a relatively
straightforward study design. Surface
markers for MDSC have been described,
both in murine and, more recently, in
human models of disease, and quantifica-
tion of (types of) MDSC in peripheral
blood samples of HIV-VL patients could
be performed through flow cytometry
[23]. A longitudinal three-arm study,
consisting of HIV+VL+, HIV+VL2,
and HIV2VL+ patients would therefore
suffice to provide a proof-of-principle for
the putative presence of MDSC during
HIV-VL coinfection. The different
groups should be carefully matched on
key factors such as ART regimen, base-
line CD4 cell count, and HIV-1 viral
load. For VL cases, analysis of peripheral
blood could possibly be complemented
with analysis of diagnostic tissue aspirates.
Cell isolation, suppression studies, and
potentially intervention trials using
MDSC targeting [24] could then be
introduced in a second phase to provide
more conclusive evidence of a central role
of MDSC in HIV-VL-associated immune
suppression.
Identification of physiologically relevant
MDSC populations in HIV-VL coinfected
patients as putative contributors to VL
therapy failure would pave the way for a
host of follow-up studies. Such studies
could, on the one hand, include research
into improved management of coinfected
patients in programmes confronted with a
high HIV-VL burden, using simple drugs
known to either deplete MDSC or inhibit
their suppressive activity, such as vitamin
A derivatives, COX2 inhibitors, and ROS
inhibitors [19,24]. On the other hand,
laboratory studies on novel methods of
averting MDSC-mediated immune sup-
pression of VL in coinfections or into the
possibility of controlling MDSC through,
e.g., the iNOS/arginase balance [19] can
be developed. In addition, a putative role
for MDSC in an HIV coinfection model
would represent a unique patho-immuno-
logical phenomenon and would be a major
addition to the existing insights into the
fundamentals of infectious diseases.
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